Annexon has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Annexon's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, Annexon's Piotroski F-Score is 4.
Competitive Comparison
For the Biotechnology subindustry, Annexon's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annexon Profitability Rank Distribution
For the Biotechnology industry and Healthcare sector, Annexon's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Annexon's Profitability Rank falls into.
Annexon Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Annexon has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Annexon's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Annexon has an F-score of 4 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Annexon (Annexon) Business Description
Traded in Other Exchanges
N/A
Address
1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
Executives
| Ted Yednock |
officer: EVP & Chief Innovation Officer |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| Muneer A Satter |
director |
C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611 |
| Jamie Dananberg |
officer: Chief Medical Officer |
3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
| Jennifer Lew |
officer: EVP & Chief Financial Officer |
2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
| Michael Overdorf |
officer: EVP & Chief Business Officer |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| Bain Capital Life Sciences Fund, L.p. |
10 percent owner |
200 CLARENDON STREET, BOSTON MA 02116 |
| Douglas Love |
director, officer: President & CEO |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| Dean Richard Artis |
officer: EVP & Chief Scientific Officer |
C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005 |
| Bettina M. Cockroft |
director |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| Larry Mattheakis |
officer: Chief Scientific Officer |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| William D. Waddill |
director |
C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080 |
| Sanjay Keswani |
officer: EVP & Chief Medical Officer |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| William H. Carson |
director |
C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016 |
| Clarus Lifesciences Iii, L.p. |
10 percent owner |
101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
| James E Flynn |
10 percent owner, other: Possible Member of 10% Group |
780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Annexon (Annexon) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANNX has been successfully added to your